# Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

> **NCT01242488** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 221 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** CDP6038
- **BIOLOGICAL:** CDP6038
- **BIOLOGICAL:** CDP6038
- **BIOLOGICAL:** Tocilizumab (Actemra or RoActemra)
- **BIOLOGICAL:** CDP6038
- **BIOLOGICAL:** CDP6038
- **BIOLOGICAL:** CDP6038
- **OTHER:** Placebo sc
- **OTHER:** Placebo sc
- **OTHER:** Placebo iv

## Key facts

- **NCT ID:** NCT01242488
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01242488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01242488, "Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01242488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*